Kidney Cancer Research
Studies Highlight Potential of Targeting HIF-2 in Kidney CancerPosted: September 29, 2016
Two new studies suggest that a new class of drugs can effectively target a molecular driver of the most common type of kidney cancer.
Two New Therapies Approved by FDA for Advanced Kidney CancerPosted: June 3, 2016
The FDA has approved two drugs, cabozantinib and lenvatinib, for patients whose advanced kidney cancers have progressed after prior treatment with antiangiogenic therapies.
Sunitinib and Sorafenib Ineffective as Adjuvant Therapies for Kidney CancerPosted: April 8, 2016
Results from a recent clinical trial show that post-surgical therapy with two anti-angiogenesis drugs does not improve progression-free survival for patients with kidney cancer and may cause serious side effects.
TCGA findings on papillary renal cell carcinoma and prostate cancerPosted: November 5, 2015
Researchers with The Cancer Genome Atlas (TCGA) report new findings on papillary renal cell carcinoma and prostate cancer.
Rare kidney tumor provides insights on role of metabolic changes in cancerPosted: August 21, 2014
Researchers in The Cancer Genome Atlas (TCGA) Network have uncovered a number of new findings about the biology and development of a rare form of kidney cancer. They found that the disease – chromophobe renal cell carcinoma – stems in part from alterations in genes in the mitochondria, the cell’s energy supplier.
Kidney cancer progression linked to shifts in tumor metabolism; Scientists with The Cancer Genome Atlas identify genomic alterations tied to tumor aggressivenessPosted: June 24, 2013
Investigators in The Cancer Genome Atlas Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer, clear cell renal cell carcinoma.
Adjuvant Everolimus for Resected Kidney CancerPosted: June 12, 2012
In this clinical trial, patients with renal cell cancer who have undergone partial or complete nephrectomy will be randomly assigned to take everolimus tablets or matching placebo tablets daily for 54 weeks.